Moens Maarten
22
3
4
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 22 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Subthreshold SCS or BMT
Role: lead
Return to Work for Persistent Spinal Pain Syndrome Type II Patients
Role: lead
Differential Target Multiplexed Spinal Cord Stimulation
Role: lead
Pain Medication Tapering for Patients With Persistent Spinal Pain Syndrome Type 2, Treated With Spinal Cord Stimulation.
Role: lead
Opinions of Healthcare Providers About a European Neuromodulation Register
Role: lead
Virtual Reality During Intrathecal Pump Refills in Children
Role: lead
Opinions of Company Representatives About Neuromodulation
Role: lead
Opinions of Healthcare Providers About Neuromodulation
Role: lead
Profiling of Post Covid-19 Infection Patients: an Online Survey
Role: lead
Intrathecal Pump Refills at Home
Role: lead
HRV and Pain Intensity
Role: lead
Dysautonomia in Patients Post COVID-19 Infection
Role: lead
pRedicting the Long-term rEsponse of High Frequency sPinal cOrd sTimulation in Patients With Failed Back Surgery Syndrome.
Role: lead
Goalsetting in Patients With Chronic Pain: a European Survey
Role: lead
Pain & Expert: Global Pain-assessment: a Prospective Registry
Role: lead
Electrodermal Activity and Respiration in Patients Treated With Spinal Cord Stimulation
Role: lead
EEG Mapping During High Frequency/High Density Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome
Role: lead
HRV in Patients Treated With Spinal Cord Stimulation
Role: lead
Goal Setting in SCS Patients: a Qualitative Review
Role: lead
Effective Connectivity in Patients Receiving Spinal Cord Stimulation: an fMRI and EEG Dynamic Causal Modeling Study
Role: lead